We also identified ARPP19 as an AML oncoprotein that increases cell viability and enhances expression of oncoproteins MYC and CDK1 and also of another oncogenic PP2A inhibitor protein, CIP2A. The gene discussed is MYC; the disease is acute myeloid leukemia.